Drug Trial Radar · NCT03571230
Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.
Last checked: Nov 19, 2026Latest source record: Jun 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
400
Planned (sponsor's estimate)
Start
Jul 1, 2018
Primary completion
Dec 30, 2019
Study completion Jan 30, 2020
Sponsor
- Lead sponsor
- Shandong UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 27, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess efficacy of 10-day antimicrobial susceptibility test guided triple therapy for the first-line treatment of Helicobacter pylori infection, then comparing it with 14-day empirical tailored therapy to tell which one has a better performance in both efficacy and safety.
Conditions
- Helicobacter Pylori Infection
- Antimicrobial Susceptibility Testing
Interventions
two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)Drug
Patients will receive a 10-day triple therapy for the H.pylori eradication. The regimen contains one PPI and two sensitive antibiotics determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone)Drug
Patients will receive a 14-day bismuth-based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.
one proton pump inhibitor(PPI)Drug
All the patients need this drug.
Colloidal Bismuth PectinDrug
All the patients treated with 14-day bismuth-based quadruple therapy need this drug.
two antibiotics for failed eradication(tetracyclin,furazolidone)Drug
If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains one PPI, Colloidal Bismuth Pectin, tetracycline and furazolidone.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Eradication rates in 2 groupsTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xiuli Zuo
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.